Last checked at 30 Jun 2022 07:01
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
2021 Annual Report and 2022 AGM Notice
London, UK, 30 June 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, announces that the following documents have now been sent to shareholders:
· Annual Report and Accounts for the year ended 31 December 2021
· Notice of Annual General Meeting ("AGM") 2022
In accordance with AIM Rule 26, these documents are also available to view on the Company's website: https://www.shieldtherapeutics.com/corporate-documents/
We are delighted to be able to welcome back our shareholders who are able to join us at our AGM. This year the Company's AGM will be held at 2pm (BST) on 27 July 2022 at the offices of Shield Therapeutics plc, Northern Design Centre, Baltic Business Quarter, Gateshead Quays, England NE8 3DF. Should restrictions be imposed that prevent this Meeting from being held in person the Company has made provisions for this Meeting to be held both virtually and electronically and details will be provided to shareholders.
If you wish to attend the AGM in your capacity as a shareholder, please bring proof of shareholding or if shares are held through a nominee account, a letter of representation, to facilitate your entry to the Meeting.
The Company will provide a facility for shareholders to join the AGM online and telephonically and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Board would request that shareholders register for the meeting and submit questions in advance, before 2.00pm (BST) on 25 July 2022.
To register for dial-in details and to submit any questions please contact Walbrook PR via email at shield@walbrookpr.com or call +44 (0)20 7933 8787.
For further information please contact:
Shield Therapeutics plc | www.shieldtherapeutics.com |
Greg Madison, CEO | +44 (0) 191 511 8500 |
Hans-Peter Rudolf, CFO | |
Nominated Adviser and Joint Broker | |
Peel Hunt LLP | |
James Steel/Christopher Golden | +44 (0)20 7418 8900 |
Joint Broker finnCap Ltd Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks |
+44 (0)20 7220 0500 |
Financial PR & IR Advisor | |
Walbrook PR | |
Paul McManus/Lianne Applegarth/Alice Woodings | +44 (0)20 7933 8780 or shield@walbrookpr.com |
Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly |
+1 617 429 3548 or jmullaly@lifesciadvisors.com |
About Accrufer®/Feraccru®
Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group